Several investigators demonstrated a potential role for classical G,,' while more recent evidence has clearly shown that a pathway including p2lras is also acti~ated.~.' One pathway that has recently become an area of intense investigation is that involving the lipid kinase, phosphatidylinositol 3-kinase (PI3K) (reviewed in Kapeller*). This enzyme is comprised of an 85-kD regulatory subunit bound to a 1 10-kD catalytic subunit, and its primary function is to catalyze the phosphorylation of inositol lipids on the D-3 hydroxyl position. Activation of PDK has been shown to occur following ligation of many growth factor receptors containing intrinsic tyrosine kinase activity, as well as receptors associated with src-like tyrosine kinases, such as the antigen receptors on T and B lymphocyte^^^'" and costimulatory receptors CD28 and CD19."-" There is increasing evidence that "crosstalk" oc- 
curs among these different pathways largely through proteinprotein interactions.
CD19 is a 95-kD protein expressed on B lymphocytes from the pre-B stage until just before terminal differentiation into plasma cells (reviewed in FearonI4). It is usually found in a complex with several other B-cell surface proteins including CD21, CD81, and Leul3. Furthermore, cross-linking CD19 simultaneously with surface IgM has been shown to augment Ig-mediated response^,'^ including activation of PI3K." Stimulation of B cells through the Ig receptor results in tyrosine phosphorylation of CD19 and is thought to recruit PI3K to the complex via its binding to CD19.I3 CD19 has also been shown to form complexes with the src-like kinases lyn" and fyn.17 Thus, CD19 appears to play a role in bringing other signaling molecules into close proximity with the Ig receptor to amplify or diversify the response.
Many of the intermolecular complexes formed in activated cells occur via binding of src homology 2 (SH2) domains to phosphorylated tyrosine residues, or binding of src homology 3 (SH3) domains to proline-rich regions in target proteins. Both fyn and PI3Kp85 bind to the tyrosine phosphorylated cytoplasmic region of CD 19.17 Another protein that has been found to associate with PI3Kp85 in Jurkat T cells,IK and with btk in B cells,I9 is the proto-oncogene c-cbl. The 120-kD c-cbl protein is expressed in lymphoid and myeloid cells, and has been shown to be phosphorylated on tyrosine after activation of TZo and B lymphocytes.'g The viral oncogene v-cbl is formed by the truncation of more than 50% of the COOH terminus of c-cbl, thus producing a protein that localizes to the nucleus, binds DNA and becomes transforming in early B-lineage and myeloid cells.*',** There is no known function of c-cbl; however, it contains 17 prolinerich regions for potential SH3 binding and multiple tyrosine residues, some of which contain SH2-binding motifs." Thus, it may be an important docking molecule in signal transduction cascades.
We have been investigating anti-Ig-mediated growth inhibition of human B-lymphoma cells, and have previously demonstrated that tyrosine phosphorylation" and activation of PI3KZ4 are both critical to this response. In this report, we examine molecular complexes involved in P13K activation following anti-Ig stimulation. We demonstrate that c-cbl, PI3Kp85, and CD19 are all phosphorylated on tyrosine following activation. In addition, we show that c-cbl forms a complex with CD19 and with the C-terminal SH2 domain of p85. Thus, both c-cbl and CD19 are involved in recruiting active PDK to the Ig receptor complex.
MATERIALS AND METHODS
The RL cell line was grown from the ascites of a patient with diffuse large cell lymphoma. It is an IgM', IgD+, B-cell line that has been shown by Southern blot analysis to be Epstein-Barr virus (EBV) genome negative and has been described previou~ly.~~ The cells are passed twice weekly in RPMI 1640 (BioWhittaker, Walkersville, MD), containing 2 mmol/L L-glutamine, 1, OOO U/mL penicillin, and 100 pg/mL streptomycin, and 10% fetal calf serum (FCS), all obtained from GIBCO (Grand Island, NY), with no other growth factors added. Normal rabbit IgG (Ryy) and rabbit anti-human IgM (RaIgM) conjugated to acrylamide beads were obtained from Irvine Scientific (Santa Ana, CA). Rabbit anticbl antiserum was obtained from Santa Cruz (Santa Cruz, CA). Anti-PI3K p85 monoclonal antibody (MoAb) and polyclonal rabbit antiserum, and the glutathione S-transferase (GST) fusion proteins of the N-terminal and C-terminal SH2 domains of PI3K p85 were all purchased from UBI (Lake Placid, NY). Anti-CD19 antibodies were purchased from Immunotech, Inc (CD19A, Westbrook, ME), Accurate Chemical and Scientific Corp (CD19B, Westbury, NY), and Cappel Organon Teknika (CD19C, Durham, NC).
RL cells were incubated with Ryy or RaIgM beads for 5 to 10 minutes, pelleted, and lysed in buffer containing 20 mmoVL Tris, 2 mmol/L EDTA, 1% NP40, 137 mmoVL NaCl, and 10% glycerol, with aprotinin (2 pg/ mL), PMSF (100 pmoVL), leupeptin (5 pg/mL), and Na,VO, (1 mmol/L) added immediately before lysing. Lysates were incubated on ice for 15 to 30 minutes, and cleared by spinning 12,000g in a microcentrifuge for 30 minutes at 4°C. Protein concentrations were determined by bicinchoninic acid (BCA) protein assay (Pierce Chem Co, Rockford, IL), and 50 pg/lane were used for straight immunoblotting. For immunoprecipitations, 200 pg to 500 pg (approximately 2 to 5 x lo6 cell equivalents, respectively) of lysate were added to eppendorf tubes containing Protein A Sepharose (Pharmacia LKB Biotech, Piscataway, NJ) and 10 pL of appropriate antisera. Tubes were rotated 2 hours to overnight, and pellets were washed three times in lysis buffer, and one time in 10 mmol/L Tris containing 0.1% NP40. For precipitations using the GST-SH2 domain-agarose conjugates, 500 pg of lysate were first precleared with protein A sepharose, rotated at 4°C with 5 pL of the conjugate, plus protein A sepharose as a carrier, and washed three times in dH20. Electrophoresis sample buffer was added to the washed pellets, samples were boiled for 10 minutes, and run on 8% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) mini-gels (Novex, Encinitas, CA). Gels were transfered to Hybond-ECL nitrocellulose (Amersham Corp, Arlington Heights, IL), and blocked for 1 hour in Tris-buffered saline containing 0.1% Tween-20 (TBST), 5% powdered milk, and 5% normal goat serum (TBST/MB/NGS). Primary antibodies were added, and blots were incubated for 2 hours at room temperature. After washing in TBST, horse-radish peroxidase-linked secondary antibodies were added to the blots in TBST/MB/NGS. Blots were then washed in TBST and developed using enhanced chemiluminescent (ECL) kits from Amersham.
Assays for PI3K activity were performed as previously described.24 Immunoprecipitates were prepared from control or anti-Ig-stimulated RL cells exactly as described above. They were washed three times in lysis buffer, and three times in 10 mmovL Tris, pH 7.4. A total of 10 pL of sonicated PI substrate (Avanti Polar Lipids, Inc, Alabaster, AL) were added to each sample Cell lines and reagents.
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and they were incubated for 10 minutes on ice. Forty microliters of kinase buffer containing 30 mmoL Hepes pH 7.4, 30 mmom MgC12, 50 pmol/L ATP, and 200 pmoVL adenosine were added, followed by 10 pCi y-"P ATP [3,OOO Ci(l1 ITBq)/mmol] (DuPont Co, NEN, Boston, MA). Samples were incubated for 20 minutes at room temperature, and the reaction was ended with 100 pL 1 mol/ L HCI. Phospholipids were extracted with 200 pL chlorofodmethan01 (1 : 1). Equal volume aliquots from the bottom chloroform layer were spotted onto thin layer chromatography plates (MCB reagents, Merck & Co, Inc, Gibbstown, NJ), and developed in chlorofod methanoVdH20/ammonium hydroxide (45:35:7.5:2.5). Plates were dried briefly and placed with X-ray film (Eastman Kodak, Rochester, NY) for 1 to 7 days at -70°C.
RESULTS AND DISCUSSION
We previously demonstrated that anti-Ig stimulation of the RL human B lymphoma cell line resulted in tyrosine phosphorylation of multiple proteins, one of which was the 85-kD subunit of P13K.24 Furthermore, we showed that both tyrosine phosphorylationz3 and activation of PI3KW were critical to the ensuing growth inhibition of anti-Ig-treated cells. In this report, we add to those findings by examining the complex of proteins that are involved in PI3K activation following anti-Ig stimulation. The cytoplasmic region of CD19 contains a consensus YXXM motif, which on activation, becomes phosphorylated and binds to the p85 SH2 domains, thus recruiting active PDK to the Ig receptor complex.I3 CD19 has also been found to be associated with the src-like kinases lyn16 and fyn.17 Similarly, the p120 protein product of the protooncogene c-cbl has been shown to be complexed with the tyrosine kinase btk in activated B cells," and with PI3Kp85 in Jurkat T cells." We were interested in determining if c-cbl and CD19 were also involved in PI3K activation in the RL cells. Because tyrosine phosphorylation is important in many of the intermolecular complexes formed, we first examined c-cbl, CD19, and p85 for antiIg-induced tyrosine phosphorylation (Fig 1) . FU cells were stimulated with control or anti-Ig conjugated to acrylamide beads for 10 minutes at 37°C. Lysates were immunoprecipitated with anti-cbl (Fig lA) , anti-p85 (Fig IB) , or three different anti-CD19 antibodies (Fig IC) , run on 10% SDS-PAGE mini-gels and transfered to nitrocellulose. Blots were probed with anti-PTyr and clearly identified phosphorylated bands of the correct molecular weights for c-cbl (120 kD), PI3Kp85 (85 kD), and CD19 (95 kD) in lysates'from the anti-Ig, but not control, treated cells. The anti-cbl and antip85 blots were then reprobed with the immunoprecipitating antibody, demonstrating that equal amounts of protein were evaluated. These data demonstrate that all three proteins are major substrates of tyrosine phosphorylation following antiIg treatment of FU cells.
We next examined the ability of these proteins to associate with each other in activated cells (Fig 2) . When lysates from control or anti-Ig-treated FU cells were immunoprecipitated with anti-p85, and blots were visualized with anti-cbl, a band with a molecular mass of 120 kD was clearly observed (Fig  2A) . Similarly, when immunoprecipitations were performed with anti-cbl, and visualized with anti-p85, an 85-kD band was seen (Fig 2B) . This blot was then reprobed (without stripping) with anti-cbl antisera to demonstrate equal , and CD19. RL cells were incubated with control beads (CBI or anti-lgM beads (FBI for 10 minutes at 37°C. Lysates (500 pg) were immunoprecipitated with anti-cbl, anti-p85, or various anti-CD19 antibodies with protein-A sepharose overnight at 4°C and run on 10% SDS mini-gels. lmmunoblots were prepared and probed with antiPTyr, anti-cbl, or anti-p85 as indicated. These results are representative of at least three separate experiments.
amounts of immunoprecipitated protein. In Fig 2C, we demonstrate that CD19 and PI3Kp85 also associate in anti-Igactivated RL cells. Finally, immunoprecipitates were made using three different anti-CD 19 antibodies, anti-PI3Kp85, anti-Class I1 major histocompatibility complex (MHC), or mouse IgGl, and analyzed by Westem blotting (Fig 2D) . The blots were probed with anti-cbl, the 120-kD c-cbl product was identified in the anti-pS5 lane, and in each anti-CD19 immunoprecipitate, but not with the mouse IgGl or anti-Class I1 MHC antibodies. --- as a docking or bridging protein among multiple signal transduction pathways. It may function in a threeway complex with CD19 and p85 to bring other molecules to the complex, perhaps as regulators of CD 19-mediated PI3K activation. Alternatively, it may form separate complexes with p85, thus linking PI3K activation with another pathway, such as the raslMapK pathway. Whether it has some other function, perhaps as a transcription factor, remains to be elucidated.
The c-cbl protein has multiple sites available for binding to other proteins via their SH2 or SH3 domains. It has been shown to bind to the SH3 domains of several proteins, including btk," Nck," pSS'gr,2x PLCY,'~ and others. In addition, it has been shown to complex with both the SH2 and SH3 domains of Grb2 in T cells." Furthermore. it contains two YXXM motifs as putative binding sites for the PI3Kp85 SH2 domains." Therefore, we investigated the ability of GST-fusion proteins containing the SH2 domains of PI3Kp8S to bind to c-cbl in anti-lg-activated RL cells (Fig  3) . Lysates from control or anti-Ig-treated cells were incubated with a GST-agarose control (11) or the GST-fusion protein containing the C-terminal SH2 domain of PI3Kp85 bound to agarose (I). the associated complexes were resolved on SDS-PAGE gels and transfered to nitrocellulose. Blots were probed with anti-PTyr (Fig 3, panels A and B, left) , or anti-cbl (Fig 3, panels A and B, right) . It is clear that multiple phosphorylated proteins bound to the p8S C-terminal SH2 domain, but not to the GST-agarose control, and one of these was identified as p120 c-cbl. Current studies are underway For personal use only. on September 24, 2017. by guest www.bloodjournal.org From to identify the other associated phosphoproteins, including the 77-kD and 95-kD bands. Similar experiments were done using the N-terminal SH2 domain GST-fusion protein; however, the results were difficult to interpret due to an extremely high background with the rabbit anti-cbl antisera. Our data demonstrate that c-cbl binds to the C-terminal SH2 domain of PI3Kp85 in activated RL cells, but do not rule out the possibility that binding via the p85 N-terminal SH2 domain, or the p85 SH3 domain, could also occur.
We next performed PI3K assays to determine if immunocomplexes containing c-cbl and CD19 exhibited increased PI3K activity in anti-Ig-activated RL cells (Fig 4) . Lysates from control or anti-Ig-treated RL cells were immunoprecipitated with anti-PTyr, anti-cbl, anti-CD19B or anti-CD19C, and PDK assays were performed as previously de~cribed.'~ It is clear that both anti-cbl and anti-CD19 were able to bring down significant levels of PI3K activity in the anti-Ig-treated, but not the control bead-treated cells, demonstrating that both c-cbl and CD19 are involved in recruiting active PI3K to the Ig receptor complex. Current data demonstrate that subunits of PI3K are members of protein families' and many different functions have been described for the products of various family members, including activation of PKCc,3° activation of S6 ribosomal k i n a~e ,~' activation of the protein kinase encoded by the Akt protooncogene," and protein trafficking and sorting? Taken together, our data show that anti-Ig stimulation of human B-lymphoma cells results in tyrosine phosphorylation of multiple proteins including c-cbl, CD19, and PI3Kp85, formation of multimolecular complexes containing c-cbl and CD19 in association with PI3Kp85, and recruitment of active PI3K to the complex. All of these events appear to be critical for receptor-mediated growth inhibition, and we are currently investigating the functional effect of Ig receptorKD19 coligation on PI3K activation and growth arrest, and the role that c-cbl plays in this response.
